Meldau 2014.
Study characteristics | |||
Patient Sampling | Cross‐sectional, consecutive, prospective | ||
Patient characteristics and setting | Presenting signs and symptoms: patients presumed to have pleural TB with any symptoms, including cough, fever, night sweats, loss of weight, haemoptysis, and chest pain, along with features consistent with a pleural effusion on chest X‐ray Age: definitive TB: median 39 years (IQR 29 to 55 years); non‐TB: median 61 years (IQR 54 to 69 years) Sex, female: 40% Children: no HIV infection: 15% Clinical setting: tertiary care hospital Past history of TB: 13% Patients on anti‐TB treatment: no Number of specimens evaluated against culture: 76 Number of specimens evaluated against a composite reference standard: 88 Laboratory level: central Country: South Africa World Bank Income Classification: middle income High TB burden: yes High TB/HIV burden: yes High MDR‐TB burden: yes |
||
Index tests | Xpert MTB/RIF WHO SOP or manufacturer's protocol followed: yes Manufacturer's involvement: no |
||
Target condition and reference standard(s) | Target condition: pleural TB Reference standard for TB detection: MGIT Reference standard for rifampicin resistance: MGIT‐DST Speciation: yes Decontamination: no |
||
Flow and timing | |||
Comparative | |||
Notes | |||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Yes | ||
Was a case‐control design avoided? | Yes | ||
Did the study avoid inappropriate exclusions? | Yes | ||
Could the selection of patients have introduced bias? | Low risk | ||
Are there concerns that the included patients and setting do not match the review question? | Unclear | ||
DOMAIN 2: Index Test (Xpert MTB/RIF) | |||
Were the index test results interpreted without knowledge of the results of the reference standard? | Yes | ||
If a threshold was used, was it pre‐specified? | Yes | ||
Could the conduct or interpretation of the index test have introduced bias? | Low risk | ||
Are there concerns that the index test, its conduct, or interpretation differ from the review question? | Low concern | ||
DOMAIN 2: Index Test (Xpert Ultra) | |||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | Yes | ||
Were the reference standard results interpreted without knowledge of the results of the index tests? | Yes | ||
For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? | Yes | ||
Could the reference standard, its conduct, or its interpretation have introduced bias? | Low risk | ||
Are there concerns that the target condition as defined by the reference standard does not match the question? | Low concern | ||
DOMAIN 4: Flow and Timing | |||
Was there an appropriate interval between index test and reference standard? | Yes | ||
Did all patients receive the same reference standard? | Yes | ||
Were all patients included in the analysis? | Yes | ||
Could the patient flow have introduced bias? | Low risk |